CBD and CBD-A share the same relationship as do THC and THC-A. CBD occurs at very low levels in raw cannabis, roughly ten percent of its levels in decarboxylated product. CBDA has no known psychoactive effects or interactions. CBDA does not activate CB1 or CB2 receptors and has negligible effects against multiple cancers. It has significant anti-inflammatory properties, reportedly more so than all other minor cannabinoids. CBD-A has no direct psychoactive effects; however, it has a potential for decarboxylating into CBD. The data on CBD psychoactivity is complex. It has no marked psychoactivity in and of itself, but it is purported to moderate many of the effects of THC. CBD appears to reduce anxiety associated with THC, possibly by blocking THC from binding to CB2 receptors (making it an inverse agonist). This interaction may explain an apparently lower rate of psychotic episodes for consumers using high-CBD cannabis, as well as how CBD mitigates THC’s negative effects on memory. CBD may also block the formation of 11-OH-THC (a powerful psychoactive metabolite of THC) in the liver, but there is controversy over whether CBD alters the pharmacokinetics (how the body interacts with the chemical) of THC. CBD is often regarded as the most medically promising cannabinoid. It has shown promise as a treatment for a range of disorders and diseases, including cancer, multiple sclerosis, schizophrenia, addiction, and epilepsy. It has been claimed to have anti-psychotic, anti-hyperalgesic, anti-convulsant, neuroprotective, anti-ischemic, anti-emetic, anti- depressive, and anti-proliferative effects.